Avomine Tablets 25mg 28

Adults: For the prevention on long journeys: one 25 mg tablet each evening at bedtime, starting the day before setting out. The duration of action is such that a second dose in 24 hours is not often necessary.

For the prevention of motion sickness on short journeys: one 25 mg tablet one or two hours before travelling or as soon after as possible.

Treatment of motion sickness: One 25 mg tablet as soon as possible and repeated the same evening followed by a third tablet the following evening.

Nausea and vomiting due to other causes

Adults: One 25 mg tablet at night is often sufficient, but two or three tablets are sometimes necessary. Alternatively, more frequent administration such as 25 mg two or three times a day may be required for some patients. It is often not necessary to give more than four of the 25 mg Avomine tablets in 24 hours.

Children: In the above indications children over 10 years of age may be given the lower adult doses described above. Children between 5 and 10 years may be given half the adult dose.

Promethazine teoclate 25 mg.
Promethazine teoclate is a long acting antihistamine with anti-emetic, central sedative and anticholinergic properties.
Also contains: Lactose, Sodium metabisulphite, Potato starch, Dextrin, Cellulose, Stearic acid, Magnesium stearate.

Other side-effects include anorexia, gastric irritation, palpitations, hypotension, arrhythmias, extrapyramidal effects, muscle spasms and tic-like movements of the head and face. Anaphylaxis, jaundice and blood dyscrasias including haemolytic anaemia rarely occur. Photosensitive skin reactions have been reported; strong sunlight should be avoided during treatment.

It may also delay the early diagnosis of intestinal obstruction or raised intracranial pressure through suppression of vomiting.

Avomine may enhance the action of any anticholinergic agent, tricyclic antidepressant, sedative or hypnotic. Alcohol should be avoided during treatment.

Avomine may interfere with immunologic urine pregnancy tests to produce false-positive and false-negative results.

Avomine should be discontinued at least 72 hours before any skin tests using allergen extracts as it may inhibit the cutaneous histamine response thus producing false-negative results.

It should not be used in pregnancy or breastfeeding unless the physician considers it essential.

Ambulant patients receiving Avomine for the first time should not be in control of vehicles or machinery for the first few days until it is established that they are not hypersensitive to the central nervous effects of the drug and do not suffer from disorientation, confusion or dizziness.

Store in the original container.